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TRANSLATIONAL RELEVANCE
Dendritic cells (DC)
Given their low frequency in blood, in vitro-produced DCs are differentiated from CD14 + monocytes cultured with cytokines (8, 9) . These immature DCs (iDC) require additional stimuli, provided by TNF-Į or LPS, to achieve a mature DCs (maDC)-like phenotype (9) .
Until now, DC vaccines have shown encouraging immunological results, although only few have been accompanied by durable clinical responses causing disappointment in the medical and scientific community (10) (11) (12) (13) . Therefore, over the past five years, a major emphasis has been placed in improving the design of DC-vaccines in order to induce proper activation, better Ag presentation and increased immunogenicity.
Optimal delivery of a wide-range pool of tumor-associated Ag (TAA) is critical for the DC-based immunotherapy. Therefore, autologous tumor cell lysates, whole tumor cells, mRNA (17) (18) (19) are valuable alternatives as TAA providers, the latter representing a standardized applicable source of melanoma-associated Ag (MAA), useful also in high-risk tumor-free patients. CTL are crucial for tumor rejection and control of dissemination (20, 21) . Since metastatic melanoma cells marginally express MHC class I (MHC-I) and not MHC-II molecules (22, 23) , their recognition requires an efficient Ag cross-presentation by DCs (24) (25) (26) . DCs cross-presentation is regulated by cytokines and TLRligands during inflammation (24) .
Recently, we showed the effectiveness of standard DC-immunization for improving longterm survival in late-stage melanoma patients (17, 19) . Herein, we propose that a lysate of heatconditioned allogeneic melanoma cells, named TRIMEL, provides a unique strategy to obtain, in only 48 h, efficient tumor-Ag presenting cells (TAPCells) with maDC-like phenotype.
Particularly, heat-shock (HS)-treatment of tumor cells induces DAMPs, which provides activation signals that trigger a fast monocyte differentiation into maDCs.
Tumor-associated DAMPs may also be responsible for an efficient Ag cross-presentation by TAPCells, thus mediating an optimal immune response in vaccinated patients. Altogether, our results provide new insights into the design of more potent and clinically effective vaccines for melanoma treatment.
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MATERIALS AND METHODS
Patients
Forty-five melanoma patients were vaccinated with TAPCells and followed-up from September 2006 until July 2010, according to the described protocol (19) . The study was performed in agreement with the Helsinki Declaration, and approved by the Bioethical Committee for Human Research of the Faculty of Medicine, University of Chile. All patients signed an informed consent.
Cell lines and cell lysates preparation
TRIMEL is a cell lysate derived from three allogeneic melanoma cell lines Mel1, Mel2 and Mel3, prepared as described (19) . Briefly, each cell line was HS-treated at 42°C for 1 h and then incubated for 2 h at 37°C. Obtained cells were mixed in equal amounts, and lysed through repeatedly freeze-thaw cycles in liquid nitrogen. The cell lysate was then sonicated and irradiated with a 60-Gy dose. The protein concentration was estimated by Bradford's method using a Biophotometer (Eppendorf). Cell lysates from PBL, prostate, and colon cancer cells were prepared following the same protocol, using commercial available cell lines. Two allogeneic primary renal cancer cell lines established at the University of Chile were used for renal cancer cell lysate preparation. The melanoma cell line FM3D was kindly provided by Dr. J. Zeuthen 
TAPCells generation
Adherent monocytes isolated from melanoma patient's PBMC were cultured in serumfree AIM-V medium (Invitrogen) with rhIL-4 (500 U/ml; US-Biological), and rhGM-CSF (800 
Flow Cytometry
The following Abs were used for cell staining: anti-HLA-ABC, HLA-DR, CD80, CD83, DC-SIGN, DEC-205, CD11c, CD86, CCR7, CD4, CD8, and CD45RO (eBioscience); and CD14
(BD). The anti-MICA mAb (R&D Systems) were used together with a secondary FITCconjugated goat anti-mouse IgG (R&D Systems). Samples were acquired on a FACSCalibur (BD), and analyzed using WinMDI 2.8 software.
ELISPOT and Proliferation assay
T cells (2 x 10 4 ) were co-cultured with APCs at different effectors/target ratios overnight.
IFN-γ secretion was tested by ELISPOT assay, as described (19) . MHC I, and MHC II blocking were performed using mAb W6/32 (eBioscience) and mAb TÜ39 (BD Pharmingen),
Immunofluorescence staining
For intracellular and surface staining, melanoma cells were fixed with 70% cold methanol or 4% paraformaldehyde, respectively, followed by incubation with purified mouse anti-human CRT mAb, aa270-390, (BD; Transduction Laboratories) and a secondary FITC- 
Western Blot
Cell pellets from APCs or tumor cells were suspended at 4ºC in RIPA lysis buffer plus protease and phosphatase inhibitors. Equal amounts of protein were separated by 12% SDS-PAGE, followed by western blotting and evaluated using anti-phospho-p65 (Cell Signaling);
anti-IțBĮ (Santa Cruz Biotech); anti-HMGB1 (BD), and anti-MART-1 (Invitrogen) Abs. Anti-ȕ-actin (Sigma-Aldrich) and anti-GAPDH (Cell Signaling) Abs were used as controls. Bands were visualized using ECL (Amersham Biosciences), and the ratio protein of interest/internal control was determined by densitometry (ImageJ software).
Skin test and T cell isolation
All patients were assessed for in vivo delayed-type hypersensitivity (DTH) reactions to TRIMEL one month after the last immunization. Ten patients were also tested before In three DTH + patients, an 8 mm excision at the DTH reaction was made, using a disposable biopsy punch (Delasco). Half the tissue sample was fixed in paraformaldehyde 1%, and paraffin-embedded specimens were immunostained with primary Abs against CD4, CD8, and CD45RO (Dako). T cells were isolated from the other half by mechanical disruption and incubated with IL-2 (250 U/ml) during three weeks and analyzed by flow cytometry. 
Statistical Analysis
RESULTS
TRIMEL induces differentiation of activated monocytes into DCs with a mature phenotype
The expression of the most common MAA; MART1, gp100, tyrosinase, NY-ESO1, MAGE1, MAGE3, MC1R, MCSP, Survivin, and Her2/neu (27, 28) was detected in the melanoma cell lines constituting TRIMEL. Mel1 and Mel3 expressed nine, and Mel2 eight out of ten MAA (data not shown). Addition of TRIMEL to AM, in the presence or absence of TNF-Į, mediated up to three-fold induction of maturation markers associated with DC maturation such as; MHC-I, MHC-II, CD80, CD86, and CD83 ( Fig. 1A and B) . Additionally, TAPCells showed increased expression of DC-associated endocytic receptors DEC-205 and DC-SIGN, and enhanced surface expression of MICA and CCR7 (Fig. 1C) . In contrast, CD14 expression was marginal on TAPCells when compared with PBMC and THP-1 cells (Fig. 1C) . with three allogeneic melanoma cell lines (Mel1, Mel2, and FM3D) supporting their ability to induce the activation of T cells ( Fig. 2A) . Neither the NK sensitive cell line K-562, nor the murine cell line NIH3T3 induced IFN-γ release ( Fig. 2A) . Elicited T cell populations were 80%
CD4
+ and 20% CD8 + and their activity was blocked with anti MHC-I or anti MHC-II mAbs (Fig   2A) . In addition, TAPCells but not AM induced autologous naïve CD4 + T cell proliferation (Fig.   2B ).
Additionally, TAPCells induced IFN-Ȗ release by a HLA-A2-restricted/MART-1 specific 
TAPCells induce MAA-specific immune response in patients
Based on our previous findings using TRIMEL-loaded standard DCs (19), a main issue to evaluate was whether TAPCells induce MAA-specific cellular immune responses in patients. To this end, 45 melanoma patients were immunized with TAPCells, producing no significant adverse reactions (Suppl. Table 1 ). Sixty four percent of patients (29 out of 45) developed TRIMEL-specific DTH reaction (Fig. 3A) , indicating CD4 + T cell activation. Importantly, CD8 + CD45RO + memory T cells were detected by immunohistochemistry in DTH + skin biopsies (Fig.   3B ), which was further confirmed after expanding the T cells isolated from these biopsies (Fig.   3C ). The majority of the patients showed a DTH + reaction against control Ags (MULTITEST   ®   ) and only one patient, out of ten tested, displayed a weak spontaneous DTH response prior treatment (data not shown).
12
The median follow-up of the stage IV patients (n=32) was 33.6 months (range 13 to 47) with an overall median survival of 15.4 months (Fig. 3D) (Fig. 3D) . Importantly, 81.1% of stage III patients (9 out of 11) remained metastasis free during the follow up (Suppl. Table 1 ).
Tumor cell lysates mediate monocyte differentiation to maDCs.
We investigated TRIMEL capacity to activate transduction signals associated to phenotypic changes in APCs. TRIMEL induced higher phosphorylation levels of NF-κB p65
than LPS (Fig. 4A) . Additionally, TRIMEL and TNF-Į, but not a conditioned allogeneic PBL lysate induced degradation of IțBĮ (Fig. 4B) . Moreover, TRIMEL, but not autologous or allogeneic PBL cell lysates, prepared under the same conditions, induced CD86 and CD83
surface expression on CD11c + DC populations, even in the presence of TNF-α (Fig. 4C) . Tumor lysates derived from conditioned prostate and colon cancer cells, but not a conditioned allogeneic PBL cell lysates, significantly increased MHC-I, CD80 and CD83 expression on CD11c + cells (Fig. 4D ).
CRT and HMGB1 are involved in TAPCells phenotypic maturation and cross presentation,
respectively.
Recently, the mobilization of CRT to the cell membrane, induced by cell stress, has been associated with increased endocytosis of stressed cells by APCs, and also with improved tumor immunogenicity in a murine model (5) . HS treatments induced robust CRT translocation from intracellular compartments to the cell membrane in all TRIMEL melanoma cell lines (Fig. 5A) .
Additionally, HS induced the release of HMGB1 by cell lines composing TRIMEL, but not by
Research. (Fig. 5B and C) . HS-treated melanoma cell lines were negative for Annexin V staining, ruling out positive HMGB1 supernatant detection due to cell destruction or attrition (Suppl. Fig.   3A and B).
To evaluate the role of tumor-derived CRT and HMGB1 in APCs activation, we stimulated AM with TRIMEL pre-incubated with anti-CRT or anti-HMGB1 specific Abs. CRT blockage inhibited TRIMEL-mediated induction of MHC-II, CD80 and CD86 (Fig. 5D, upper   panel) . In contrast, MHC-I and CD83 expression was not affected on these cells (Fig. 5D, upper 
panel). TRIMEL pre-treatment with a HMGB1 neutralizing Ab reduced MHC-I expression on
APCs, but the expression of other surface markers was not affected (Fig. 5D, lower panel) . The involvement of CRT and HMGB1 in DC-mediated Ag cross presentation was also assessed.
Stimulation of APCs from three melanoma patients with TRIMEL induced a five-fold increase
of IFN-γ release by the CdL43-1 clone, compared to APCs stimulated with a non HS-treated melanoma cell lysate (Fig. 6A) . No differences in endocytosis rates were detected in HS-treated (TRIMEL) vs. non HS-treated (melanoma lysate) (Suppl. Fig. 4) . Interesting, pre-treatment with an anti-HMGB1 specific Ab attenuated TRIMEL-mediated IFN-γ release by the CdL43-1 clone (Fig. 6B) . Moreover, supernatant from HS-treated melanoma cells (TRIMEL) added to non HStreated melanoma lysate, restored and improved Ag recognition by the clone CdL43-1 (Fig. 6B ).
This effect was blocked when the supernatant were pre-treated with an anti-HMGB1 Ab, suggesting a role for the released HMGB1 in the induction of Ag cross-presentation (Fig. 6B) . TAPCells, tested in 45 stage I, III, and IV melanoma patients, proved to be well tolerated, and except for the presence of vitiligo in two cases, no major side effects were observed (Suppl. Research. 
Herein, we demonstrated that TRIMEL not only provides a broad panel of shared Ag to DCs, but also is essential for the acquisition of TAPCells functional phenotype. Thus, TRIMEL but not a conditioned allogeneic PBL lysate activates transduction signal pathways on APCs, particularly the transcription factor NF-κB associated to phenotypic changes. Furthermore, neither autologous nor allogeneic conditioned non-tumor cell lysates induced surface expression of maturation markers, suggesting that factors present in the tumor cells induce the differentiation process. This may be a general property of some tumors because also lysates derived from prostate and colon cancer cells significantly increase MHC and costimulatory molecules expression on DCs. Although unexplained, tumor cells, but not primary cells, induce DCs maturation after necrosis, which may be associated to over-expression of DAMPs by human neoplasms (40, 41) .
Interestingly, APCs loaded with a lysate composed by non-stressed melanoma cells showed a reduced capacity to activate a MAA-specific CTLs as compared to HS conditioning, previous to the cell lysis. In this respect, DCs primed with a HS-treated tumor cell lysate, followed by an in situ boost with radiofrequency thermal ablation, prevents local tumor recurrence in a murine model (42) . The use of cell lysates as Ag source produce clinical responses in several tumor models (43) (44) (45) (46) , suggesting that our tumor cell conditioning may have an impact in the design of more optimal protocols. HS-treatment previous to the tumor cell lysis causes CRT translocation (most likely, from the endoplasmic reticulum) to the plasma membrane, and HMGB1 release to the extracellular media. We showed that HS-induced CRT translocation to the plasma membrane directly contributes to maturation of TAPCells. Specific blockage of CRT, not only inhibited MHC-II and co-stimulatory molecules surface expression, but also reduces the capacity of CTLs to 
recognize MAA on TAPCells associated to the induction of a deficient DCs phenotype.
Although CRT translocation caused by cytostatic drugs, or other stresses, increases both the phagocytic capacity and immunogenicity of DCs in a murine model (5), we could not detect differences in the endocytic capacity mediated by CRT-membrane mobilization (Suppl . Fig. 4 ).
Since murine bone marrow-derived DC precursors are different from human monocyte-derived DCs, perhaps they react differently to similar stimulus (47). Additionally, our results show that tumor cells, but not normal PBL, release HMGB1 after HS-treatment. Interestingly, the lack of released HMGB1 in HS-treated PBL supernatants and their low expression in renal tumor lysate (Suppl. effectors cells of at least three independent experiments; bars indicate SD; *p < 0.05, **p < 0.01.
